High-Dose Chemotherapy for Breast Cancer

Letters1 June 1997High-Dose Chemotherapy for Breast CancerElisabeth G.E. de Vries, Carel C. Mastenbroek, and Sjoerd RodenhuisElisabeth G.E. de VriesUniversity Hospital Gronigen, Gronigen, the Netherlands.Dutch Health Insurance Council, the Netherlands.Netherlands Cancer Institute, Amsterdam, the Netherlands.Search for more papers by this author, Carel C. MastenbroekUniversity Hospital Gronigen, Gronigen, the Netherlands.Dutch Health Insurance Council, the Netherlands.Netherlands Cancer Institute, Amsterdam, the Netherlands.Search for more papers by this author, and Sjoerd RodenhuisUniversity Hospital Gronigen, Gronigen, the Netherlands.Dutch Health Insurance Council, the Netherlands.Netherlands Cancer Institute, Amsterdam, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-11-199706010-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gradishar and colleagues [1] focused on the rationale for the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast cancer. They express the concern that few patients are entered into randomized trials even though there is no definite proof of the value of high-dose chemotherapy in the adjuvant setting. The authors reviewed the efforts to overcome physician and patient biases so that the trials can be completed. Somewhat to our surprise, the authors did not indicate that this patient and physician bias is particularly a problem in the United States but that several well-accruing, ...References1. Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med. 1996; 125:599-604. Google Scholar2. De Vries EG, Ten Vergert EM, Mastenbroek CG, Dalesio O, Rodenhuis S. Breast cancer studies in the Netherlands. Lancet. 1996; 348:407-8. Google Scholar Author, Article, and Disclosure InformationAffiliations: University Hospital Gronigen, Gronigen, the Netherlands.Dutch Health Insurance Council, the Netherlands.Netherlands Cancer Institute, Amsterdam, the Netherlands. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHigh dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancerHigh dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer 1 June 1997Volume 126, Issue 11Page: 917-918KeywordsBreast cancerCyclophosphamideData managementDrugsForecastingGrowth factorsHealth insuranceHigh-dose chemotherapyLymph nodesRandomized trials Issue Published: 1 June 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...